PMID- 22697297
OWN - NLM
STAT- MEDLINE
DCOM- 20130214
LR  - 20161125
IS  - 1365-3148 (Electronic)
IS  - 0958-7578 (Linking)
VI  - 22
IP  - 5
DP  - 2012 Oct
TI  - National audit of the use of fibrinogen concentrate to correct 
      hypofibrinogenaemia.
PG  - 350-5
LID - 10.1111/j.1365-3148.2012.01168.x [doi]
AB  - BACKGROUND: Massive haemorrhage occurs in a variety of clinical settings 
      resulting in consumptive and dilutional coagulopathies leading to 
      hypofibrinogenaemia. METHODS/MATERIALS: A prospective observational national 
      cohort study was performed between November 2008 and June 2010 to collect safety 
      data on the off-label use of a fibrinogen concentrate to treat acquired 
      hypofibrinogenaemia. RESULTS: A prospective cohort of 63 patients with varying 
      causes of hypofibrinogenaemia resulted from this data collection. A single 
      infusion of fibrinogen concentrate was given in 49 (77%) of patients studied and 
      12 received more than one infusion. The median inter-quartile range (IQR) dose of 
      fibrinogen infused was 49 (26-61) mg kg(-1). The median (IQR) fibrinogen level 
      before and after infusion was 0.9 (0.6-1.3) and 1.8 (1.4-4.3) g L(-1), 
      respectively (P < 0.001). In 31 patients (67%), bleeding stopped within 4 h and 
      fibrinogen was reported to have contributed to this outcome by the treating 
      clinicians. In 84% of cases the treating clinician reported that the use of 
      fibrinogen concentrate reduced the rate of bleeding. Fibrinogen was associated 
      with a statistically significant reduction in red blood cell transfusion (median 
      4 units before and 0 units after, P < 0.001) and fresh frozen plasma infusion 
      (median 4 units before and 0 units after, P < 0.001). Three venous and one 
      arterial non-fatal thrombotic events were recorded in the patients treated with 
      fibrinogen. CONCLUSION: Fibrinogen concentrate can be used to correct 
      hypofibrinogenaemia and may reduce blood product usage.
CI  - (c) 2012 The Authors. Transfusion Medicine (c) 2012 British Blood Transfusion 
      Society.
FAU - Gollop, N D
AU  - Gollop ND
AD  - The School of Medicine, University Hospital of Wales and School of Medicine, 
      Cardiff University Cardiff, UK.
FAU - Chilcott, J
AU  - Chilcott J
FAU - Benton, A
AU  - Benton A
FAU - Rayment, R
AU  - Rayment R
FAU - Jones, J
AU  - Jones J
FAU - Collins, P W
AU  - Collins PW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20120614
PL  - England
TA  - Transfus Med
JT  - Transfusion medicine (Oxford, England)
JID - 9301182
RN  - 0 (Coagulants)
RN  - 9001-32-5 (Fibrinogen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Afibrinogenemia/blood/*drug therapy
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Child, Preschool
MH  - Coagulants/*administration & dosage
MH  - Cohort Studies
MH  - Female
MH  - Fibrinogen/*administration & dosage
MH  - Hemorrhage/blood/drug therapy
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Medical Audit
MH  - Middle Aged
MH  - Prospective Studies
MH  - United Kingdom
EDAT- 2012/06/16 06:00
MHDA- 2013/02/15 06:00
CRDT- 2012/06/16 06:00
PHST- 2012/02/10 00:00 [received]
PHST- 2012/05/05 00:00 [accepted]
PHST- 2012/06/16 06:00 [entrez]
PHST- 2012/06/16 06:00 [pubmed]
PHST- 2013/02/15 06:00 [medline]
AID - 10.1111/j.1365-3148.2012.01168.x [doi]
PST - ppublish
SO  - Transfus Med. 2012 Oct;22(5):350-5. doi: 10.1111/j.1365-3148.2012.01168.x. Epub 
      2012 Jun 14.